logo
Procter & Gamble hikes U.S. prices amid tariff challenges, CEO change

Procter & Gamble hikes U.S. prices amid tariff challenges, CEO change

CTV News3 days ago
Procter & Gamble on Tuesday forecast annual results largely below estimates and said it would raise prices on some products in the U.S., a day after naming insider Shailesh Jejurikar as CEO to steer it through tariff uncertainty.
The consumer goods bellwether's shares were down 1.2 per cent in volatile early trading.
P&G, which topped fourth-quarter estimates, said it would raise prices on about a quarter of its products in the U.S., starting this month, to help offset the cost of new tariffs imposed by U.S. President Donald Trump.
The price hikes have been communicated to retailers such as Walmart and Target and are in the mid-single digits across categories, a spokesperson said, and will be seen on shelves starting in August.
P&G expects fiscal 2026 annual net sales growth of between one and five per cent, largely below estimates of a 3.09 per cent growth.
Market growth slowed from where it was at the start of the year in both the U.S. and in Europe, and volatile macroeconomic, geopolitical and consumer dynamics were resulting in headwinds that were not anticipated at the start of the year, CFO Andre Schulten said during a call with journalists.
'The consumer clearly is more selective in terms of shopping behavior in our categories and we see a desire to find value either by going into larger pack sizes in club channel or online or big box retailers or by lowering the cash outlay,' Schulten said.
The comments from the world's largest consumer goods maker reinforce how consumers, particularly in the lower-income category, are seeking value as they look to stretch their household budgets. Packaged food maker Nestle said last week that consumers in North America remained weak.
Still, organic sales grew about two per cent in fiscal 2025, driven by P&G's portfolio of branded pantry staples, as well as higher pricing, particularly for fresher products.
'Given the immense pressure put on U.S. consumers in particular, the organic growth is a very good sign that long-term earnings projections should hold up,' said Brian Mulberry, portfolio manager at Zacks Investment Management.
P&G, which makes household basics spanning from Bounty paper towel to Metamucil fiber supplements, estimated tariffs will increase its costs by about US$1 billion before tax for fiscal 2026. That compares with projections of between US$1 billion and US$1.5 billion made in April.
The company rolled out a restructuring effort in June to exit some brands and cut about 7,000 jobs over the next two years to increase productivity. Prices rose about one per cent in the fourth quarter, while volumes were flat.
P&G expects fiscal 2026 core net earnings per share growth in the range of US$6.83 and US$7.09, compared with estimates of US$6.99, according to estimates compiled by LSEG.
For the three months ended June 30, the company's revenue rose to US$20.89 billion, topping estimates of US$20.82 billion, while core profit of US$1.48 per share also beat expectations.
---
Reporting by Juveria Tabassum in Bengaluru and Jessica DiNapoli in New York; Editing by Sriraj Kalluvila
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Premiers Smith, Moe disappointed by Trump's tariffs but most exports remain duty-free
Premiers Smith, Moe disappointed by Trump's tariffs but most exports remain duty-free

Toronto Star

time27 minutes ago

  • Toronto Star

Premiers Smith, Moe disappointed by Trump's tariffs but most exports remain duty-free

REGINA - The premiers of Alberta and Saskatchewan say they're disappointed by higher tariffs from U.S. President Donald Trump but pleased the majority of their exports won't face duties. Saskatchewan Premier Scott Moe says the Canada-United States-Mexico trade agreement remains in place, allowing 95 per cent of his province's exports to move into the United States tariff-free.

Canada should refrain from any retaliatory measures: Sask. Premier Moe on U.S. tariffs hike
Canada should refrain from any retaliatory measures: Sask. Premier Moe on U.S. tariffs hike

CTV News

time27 minutes ago

  • CTV News

Canada should refrain from any retaliatory measures: Sask. Premier Moe on U.S. tariffs hike

Premier of Saskatchewan Scott Moe speaks to media following the First Minister's Meeting in Saskatoon, Sask., Monday, June 2, 2025. THE CANADIAN PRESS/Liam Richards Saskatchewan Premier Scott Moe says U.S. President Donald Trump's new 35 per cent tariffs are disappointing and that Canada should refrain from any retaliatory measures that would cause harm to Canada's economy. However, he says that efforts remain in effect to ensure the Canada-U.S.-Mexico trade agreement (CUSMA) remains in effect. 'While Saskatchewan is disappointed in the Trump administration's decision to increase tariffs on non-CUSMA compliant Canadian goods to 35 per cent, Canada's efforts to ensure CUSMA remains in effect means that 95 per cent of Saskatchewan exports to the U.S. will remain tariff-free,' he said in a statement. Moe says CUSMA remaining in effect is very significant given the U.S. has imposed across-the-board tariffs on many countries. Trump signed an executive order activating tariffs against 68 countries and the European Union Thursday evening. New tariffs of 35 per cent on Canadian exports, effective Friday, exclude products under CUSMA, the White House has said. Moe says Canadian exports that remain tariff-free now have a competitive advantage relative to other countries facing tariffs on the same products. 'Our government will continue to engage with U.S. businesses and lawmakers to improve our trade relationship while continuing to expand our export markets to over 160 countries around the world that buy Saskatchewan products,' he said. He says Saskatchewan will also continue to press the federal government to adopt the 'Strong Saskatchewan, Strong Canada Plan' to approve economic infrastructure projects and eliminate regulations hindering economic development. Moe is expected to speak to reporters on Friday at 12 p.m., which can be livestreamed at the top of this article. -More to come…

Unlocking ROI in Medical Imaging: The Strategic Growth of the Global MRI Systems Market
Unlocking ROI in Medical Imaging: The Strategic Growth of the Global MRI Systems Market

Globe and Mail

time27 minutes ago

  • Globe and Mail

Unlocking ROI in Medical Imaging: The Strategic Growth of the Global MRI Systems Market

"The key players profiled in the MRI systems market are Siemens Healthineers (Germany), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), FUJIFILM Corporation (Japan), Canon Inc. (Japan), Fonar Corporation (US)" Browse 226 market data Tables and 56 Figures spread through 259 Pages and in-depth TOC on "MRI Systems Market by Architecture (Open, Closed), Field Strength (High Field MRI Systems & Low Field MRI Systems), Design (Portable MRI Systems, Fixed/Stationary MRI Systems), End User (Hospitals, Diagnostic Clinic), Region - Global Forecast to 2030 Why MRI Systems Are a Smart Long-Term Investment As the healthcare industry undergoes a paradigm shift toward precision medicine and value-based care, Magnetic Resonance Imaging (MRI) has emerged as a cornerstone of diagnostic excellence. Forecasted to grow from USD 6.15 billion in 2024 to USD 9.01 billion by 2030, the MRI systems market offers robust opportunities for healthcare providers, OEMs, and strategic investors alike. For C-level executives, the MRI market represents more than just imaging hardware—it's a long-term investment in AI-enabled diagnostics, faster clinical workflows, and improved patient outcomes. With a CAGR of 6.5%, the sector is primed for innovation-led expansion and solid ROI. Market Snapshot: A Growing Industry with Predictable ROI 2024 Market Size: USD 6.15 Billion 2025 Projection: USD 6.56 Billion 2030 Forecast: USD 9.01 Billion CAGR: 6.5% (2024–2030) Driving Forces: Rise in neurological and musculoskeletal conditions Global aging population Increasing oncology imaging requirements Advancements in ultra-high-field MRI Favorable regulatory and reimbursement environments High-Value Applications: Brain & Neurological MRI Lead the Charge According to market research, brain and neurological MRI is the largest and fastest-growing application segment. This growth is driven by the surge in neurodegenerative disorders such as Alzheimer's, Parkinson's, epilepsy, and stroke. For hospital executives and diagnostic center owners, investing in neuro-MRI systems ensures better diagnostic precision, faster patient throughput, and enhanced clinical reputation—all critical ROI levers. Key ROI Insights: Faster diagnosis → Reduced inpatient days High diagnostic accuracy → Lower misdiagnosis risk Software upgrades → Extended equipment lifecycle Field Strength Matters: Ultra-High-Field MRI Is the Future The market is categorized by field strength: Low-to-mid-field High & very-high-field Ultra-high-field Among these, ultra-high-field MRI is experiencing the highest CAGR. These systems offer: Superior Signal-to-Noise Ratio (SNR) Enhanced contrast resolution Exceptional neuro and cardiovascular imaging As hospitals seek competitive clinical differentiation, ultra-high-field MRI investments will become a strategic priority. End User Analysis: Why Hospitals Dominate the Market Hospitals are currently the largest adopters of MRI systems and are expected to continue dominating. Their edge lies in: Access to capital investment budgets Integrated multi-specialty diagnostic care Alignment with value-based reimbursement models For CFOs and CIOs, the integration of MRI into enterprise imaging architecture ensures: Optimized resource allocation Predictable revenue from advanced imaging Better data utilization for AI algorithms Geographical Insights: North America Sets the Pace North America leads the global MRI systems market due to: Cutting-edge healthcare infrastructure Strong presence of OEMs and distributors Favorable regulatory and R&D support Healthcare providers in the U.S. are focusing on: High-throughput MRI centers Remote scanning capabilities Integration with AI and cloud-based radiology tools For OEMs and med-tech investors, the region is ripe for partnerships, pilot programs, and acquisitions. Request Sample Pages : Top Companies to Watch: Strategic Moves from Market Leaders 1. Siemens Healthineers (Germany) A frontrunner with a global manufacturing and R&D footprint, Siemens has deep investments in molecular imaging, AI-driven diagnostics, and portable MRI innovations. 2. GE HealthCare (US) GE's strategic growth is powered by inorganic acquisitions and global reach. Their solutions span molecular imaging, cardiac MRI, and biopharma integration. 3. Philips (Netherlands) Philips focuses on image-guided therapy, ultrasound integration, and cloud-connected platforms. Their Diagnosis & Treatment segment is a growth engine for MRI innovation. Other notable players: Canon Inc. (Japan) FUJIFILM Corporation (Japan) Fonar Corporation (US) Esaote S.p.A (Italy) United Imaging Healthcare (China) Innovation Trends: The Future of MRI is AI, Portability & Cloud Emerging innovation themes include: AI-enhanced image reconstruction Low-helium or helium-free systems Cloud-integrated radiology reporting Portable and point-of-care MRI Strategic Implications for C-suite: AI & ML tools embedded into MRI workflows can increase operational efficiency by 20–30% Cloud PACS integration ensures interoperability across multisite locations Portability introduces new revenue streams in mobile diagnostics and remote care What This Means for Healthcare Decision-Makers For CIOs, CFOs, and Clinical Executives, investing in MRI systems is no longer about hardware—it's a holistic ecosystem decision involving software, analytics, AI, and patient experience. Key Questions Executives Are Asking: How does MRI investment impact long-term patient retention and referral growth? Can we bundle MRI services with AI diagnostics for higher margins? What's the total cost of ownership (TCO) versus projected operational ROI? Conclusion: MRI Systems as a Strategic Differentiator in 2030 As demand for advanced diagnostic capabilities surges globally, MRI systems stand out as a high-impact, high-yield investment. With expanding clinical applications, regulatory support, and innovation momentum, this is an opportunity that healthcare leaders cannot afford to overlook. Whether you're managing hospital procurement, evaluating M&A options in the imaging space, or scaling a diagnostic chain, the MRI systems market offers sustainable ROI, technological resilience, and significant growth potential through 2030. For more information, Inquire Now!

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store